The Rising Influence of Rising Affluence

[semi_infinite]

ISRG has world wide numbers in their most recent downloadable investor presentation. It comes out to around 4 procedures per day per system or extrapolate to around 860K procedures for 2017. Their release of a "cheaper" Da Vinci X model seems to have bumped the adoption rate up recently. It may not be a bad idea for them to aim for zero margins for system sales and just collect on the high margin instruments. Looks like they are going after the ENT surgery market with Da Vinci SP and lung biopsy market with Fosun JV via flexible catheter Latter items seem like roundoff error distractions.

http://phx.corporate-ir.net/phoenix.zhtml?c=122359&p=irol-irhome

TRXC has last year's numbers from US and EU in their Stifel slides and they put it around 600K procedures. Stifel slides also have macro picture on abdominal surgery procedures that they are going after. Seems consistent with ISRG numbers.

http://files.shareholder.com/downloads/AMDA-29PLRN/5738432375x0x964120/A22172D2-BE4D-4A6E-8E9D-83B16F643272/2017-11-14_Stifel_FINAL.pdf